In June, Novavax announced that its vaccine had proved about 90% effective against symptomatic COVID-19 in a study of nearly 30,000 people in the U.S. and Mexico. U.S.-based Novavax has asked the World Health Organization to approve its COVID-19 vaccine for emergency use so it can be part of the COVAX global vaccine program.